SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by anticipation for upcoming clinical data presentations and a potential BLA submission later this year. The community is actively discussing the stock's high short interest and limited effective float, fueling speculation about a possible short squeeze and long-term valuation potential relative to sector peers.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Dow Inc. is trending as investors weigh significant operational challenges against potential strategic upside, including recent job cut announcements and efforts to optimize EBITDA. The community remains divided, with some traders debating whether the stock is a deep-value opportunity for long-term recovery and dividend income, while others express frustration over persistent weak demand and ongoing supply chain headwinds.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is facing extreme selling pressure and intense community scrutiny as investors grapple with multiple compression, executive departures, and a lack of positive guidance. While some see a generational buying opportunity near multi-year lows, others remain deeply frustrated by the stock's persistent underperformance and the CEO's lack of communication regarding rumored AI-driven catalysts.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing intense downward pressure despite fresh capital injections from the Saudi PIF and Uber, as investors express skepticism over persistent dilution and the appointment of a new CEO with an industrial, non-automotive background. The community is sharply divided, with bulls pointing to the company's advanced EV technology and long-term potential in the robotaxi market, while bears remain focused on high cash burn, recurring share offerings, and the risk of further reverse splits.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently trending as investors weigh its role as a high-beta proxy for Bitcoin against broader concerns over the Clarity Act, which remains a key focus for market participants anticipating potential regulatory shifts. The community is actively discussing Coinbase's technical setup and its correlation with BTC, with many traders debating whether the stock is setting up for a rebound or facing further downside risk.

VanEck ETF Trust - VanEck Junior Gold Miners ETF

VanEck Junior Gold Miners ETF

Junior gold miners are capturing significant attention as the ETF demonstrates a robust nested impulse rally, signaling strong bullish momentum that has the community actively debating the durability of the sector's breakout. Investors are closely monitoring the interplay between record gold prices and the sector's valuation, with many bullish traders viewing any short-term volatility as a strategic accumulation opportunity.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently in the spotlight as investors brace for the upcoming BlueBird 7 launch, with the community actively debating whether the stock is primed for a major breakout or if the event remains priced in. Investors are closely monitoring manufacturing progress and batch shipment updates as key catalysts, while discussions remain polarized between those confident in long-term deployment goals and others wary of execution timelines and institutional selling pressure.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as investors react to a significant volume of convertible note offerings, causing short-term price volatility while fueling speculation about strategic acquisitions or pipeline expansions. Meanwhile, the community remains divided between long-term bulls highlighting strong institutional backing and a robust clinical pipeline, and frustrated retail holders concerned by management's dilution strategy and the stock's struggle to maintain upward momentum.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending as investors weigh strong backlog growth and a pending acquisition against volatility stemming from Middle East energy infrastructure disruptions. While the community actively debates whether the stock's current price accurately reflects elevated oil prices and deepwater demand, many are monitoring for a potential short squeeze given the high percentage of float sold short.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is generating buzz as investors speculate on a potential supply shock due to its limited 10 million token cap, while the community closely monitors potential institutional interest and upcoming decentralized finance (DeFi) developments. Despite varied sentiment regarding historical performance, the discussion is heavily fueled by anticipation of broader market momentum and the potential for a reversal as traders track key support and resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Decrease in Short Interest

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totaling 234,254 shares, a...

Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) was the target of a significant drop in short interest in March. As of March 13th, there was short interest totaling 288,865 shares, a drop of 22.7...

Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) saw a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 373,692 shares, a drop of 19.5...

Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3% - Time to Sell?

Jyong Biotech (NASDAQ:MENS) Shares Down 12.3% - Here's Why...

Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 649,057 shares, an...

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totaling 252,374 shares, an increase of...

Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Still a Buy?

Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Time to Buy...

Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3% - Here's What Happened

Jyong Biotech (NASDAQ:MENS) Shares Down 19.3% - Should You Sell...

Jyong Biotech (NASDAQ:MENS) Trading Down 5.9% - Here's Why

Jyong Biotech (NASDAQ:MENS) Shares Down 5.9% - Here's Why...

Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th

Jyong Biotech's (NASDAQ:MENS - Get Free Report) lock-up period will expire on Monday, December 15th. Jyong Biotech had issued 2,666,667 shares in its public offering on June 17th. The total size of...

Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. It offers plant-derived drugs that focus on the treatment of urinary system diseases. The company was founded by Fu Feng Kuo in July 2002 and is headquartered in New Taipei, Taiwan.

MENS
Jyong Biotech Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest MENS News

MENSJyong Biotech Ltd.